WallStAnalyst.com: Social Media Stocks See Turbulent Times Ahead; Elusive Alzheimer’s Drug Proves Potential Golden Egg

NEW YORK--()--Wall St. Analyst (www.wallstanalyst.com) has announced its comprehensive market summary that analyzes the most relevant news, events, and economic releases. This edition of the newsletter provides an insight into the financial performance of social media companies during the last quarter and how they have added garnered subscribers and advertisement revenue. The newsletter also throws the spotlight on how insider trading helped portfolio managers earn huge amount of money on undisclosed results of drug trials pertaining to potential breakthrough remedies for major diseases.

Social Media Stocks Post Mixed Results, Target MAU and Ad Growth
The earnings of major social media stocks mirrors turbulent times ahead, with the mixed results of these companies puzzling market watchers regarding their overblown valuation despite poor results. These companies are looking at sustaining their MAUs and ad revenue while improving algorithms in an intensely competitive market to meet investor expectations. More details about the drivers in this industry is available at

http://wallstanalyst.com/research-desk/hot-w/1195-the-social-media-conundrum

Insider Trading Lands Portfolio Managers in Soup after Exposé
WallStAnalyst.com analyses how a major exposé of the biggest lucrative insider trading scheme ever landed portfolio managers in a soup after they used undisclosed data relating to drug trials to build a short position. This in turn enabled them to earn huge profits when the stocks of companies involved in these drug trials tanked after the public announcement of the trial results. More details about the largest ever US insider trading scam is available at

http://wallstanalyst.com/blog/entry/the-tale-of-an-insider-trading-leak-gone-wrong

Weak Earnings Season Paves the Way for Cautious Outlook
WallStAnalyst.com analyzes how the weak earnings of major US based companies have prompted management to provide a cautious outlook for the forthcoming quarters. With the US market achieving a saturation of sorts, most of these firms are looking at the emerging nations to drive their future growth. The earnings reports of some of these companies show that currency fluctuations have played a major role in denting profits. More details about the earnings reports is available at

http://wallstanalyst.com/research-desk/market-monitoring/1194-earnings-release-07-feb-2014

Focus Concepts, Sectors, and Companies
Facebook
LinkedIn
Twitter
Pfizer Inc.
Merck & Co
Johnson & Johnson
AstraZeneca
Medivation Inc.
Elan Corp.
Wyeth
Eli Lilly

For more information visit www.wallstanalyst.com

Contacts

Wall Street Analyst
Ms. Vani Rao, Chief Editor
+1-347-394-0245
press@wallstanalyst.com

Release Summary

WallStAnalyst.com: Social Media Stocks See Turbulent Times Ahead; Elusive Alzheimer’s Drug Proves Potential Golden Egg

Sharing

Contacts

Wall Street Analyst
Ms. Vani Rao, Chief Editor
+1-347-394-0245
press@wallstanalyst.com